The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...

for SPRAVATO ® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate ...

SPRAVATO® is unique and works by targeting glutamate, which is the most abundant excitatory neurotransmitter in the brain.6 The mechanism by which esketamine exerts its antidepressant effect is ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

SPRAVATO® is unique and works by targeting glutamate, which is the most abundant excitatory neurotransmitter in the brain.6 The mechanism by which esketamine exerts its antidepressant effect ...

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

However, Spravato contains a different form of ketamine than the version that is used intravenously—a chemical sibling called esketamine. In the years since its approval, Spravato and ketamine ...